CIK 0001787400 · Pharmaceutical Preparations (SIC 2834) · Nasdaq · incorporated in DE · fiscal year ends 12/31
| FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|
| Revenue (USD) | 0 | 0 | ||
| Net income (USD) | -117.5 M | -113.8 M | -86.1 M | |
| Diluted EPS (USD/shares) | -1.41 | -2.4 | -2.61 |
| Filed | Form | Description | Period |
|---|---|---|---|
| 2026-08-10 | 10-Q | 10-Q | 2026-06-30 |
| 2026-08-10 | 8-K | 8-K items 2.02,9.01 | 2026-08-10 |
| 2026-06-22 | 4 | 4 | 2026-06-18 |
| 2026-06-11 | 8-K | 8-K items 5.07,9.01 | 2026-06-10 |
| 2026-06-11 | 4 | 4 | 2026-06-10 |
| 2026-06-11 | 4 | 4 | 2026-06-10 |
| 2026-06-11 | 4 | 4 | 2026-06-10 |
| 2026-06-11 | 4 | 4 | 2026-06-10 |
| 2026-06-11 | 4 | 4 | 2026-06-10 |
| 2026-06-11 | 4 | 4 | 2026-06-10 |
| 2026-06-11 | 4 | 4 | 2026-06-10 |
| 2026-06-11 | 4 | 4 | 2026-06-10 |
| 2026-05-19 | SCHEDULE 13D/A | SCHEDULE 13D/A | |
| 2026-05-12 | 10-Q | 10-Q | 2026-03-31 |
| 2026-05-12 | 8-K | 8-K items 2.02,9.01 | 2026-05-12 |
| 2026-04-23 | ARS | ARS | 2025-12-31 |
| 2026-04-23 | DEFA14A | DEFA14A | |
| 2026-04-23 | DEF 14A | DEF 14A | 2026-06-10 |
| 2026-04-03 | EFFECT | EFFECT items ,, | |
| 2026-04-03 | 424B5 | 424B5 | |
| 2026-04-01 | CORRESP | CORRESP | |
| 2026-03-31 | UPLOAD | UPLOAD | |
| 2026-03-26 | 8-K | 8-K items 8.01,9.01 | 2026-03-25 |
| 2026-03-25 | S-3 | S-3 | |
| 2026-03-25 | 10-K | 10-K | 2025-12-31 |
Forms on file (last 1,000): 4 184, 8-K 60, 3 32, 10-Q 19, SC 13G/A 16, SC 13G 14, SC 13D/A 12, CORRESP 9. Source: SEC EDGAR, as filed; this page is public data and not investment advice.
GET https://store.agentexchange.work/gw/filings/company?ticker=NKTX (0.002 USD), /gw/filings/filings?ticker=NKTX&form=8-K, /gw/filings/facts?ticker=NKTX&concept=Revenues, full-text /gw/filings/search?q=.... Pay per call in USDC (x402) or with a 19 USD card key for 1,000 calls. Catalogue · llms.txtUpdated from EDGAR within 30 minutes of a filing. Agent Exchange